Sangui BioTech International, Inc.

Website Links

Description

Witten, Germany, July 16, 2013 MEDiLAB c.o.o., Zagreb, Croatia, undertakes the distribution of the wound therapeutic Granulox in Slovenia, Croatia, Serbia, Bosnia and Herzegovina as well as Macedonia with a combined population of over 20 million inhabitants. A contract to this effect was now signed with global licensee SastoMed GmbH. MEDiLAB was established in 1991 and employs more than 120 employees in its three operating units. The company which has repeatedly obtained excellence awards represents companies such as B. BRAUN, BAYER Diabetes Care, Siemens MSD, Diesse and Buhlmann.

We provide this information with no assurances or warranty of any kind, express or implied. Also excluded are all implied warranties related to the merchantability, suitability for certain purposes or compliance with laws and patents. Even if we assume that the information we provide is accurate it may however include errors or inaccuracies. On our web pages you will also find links to other websites on the internet. We would like to point out that we have no influence on the design or content of the pages linked to.

Witten, Germany, April 22, 2013 The sales area for Granulox the Sangui developed wound therapeutic is being expanded. SastoMed GmbH global licensee for the distribution of Granulox has come to a sales agreement with BiologiQ thus securing the first partner for the planned European network. The Apeldoorn, Netherlands, based wound management specialists have been operating successfully in the Benelux markets since 2005 and have already implemented some initial marketing activities. Actual sales are to be started in summer.

A helpful product was researched and developed for the healing of these chronic wounds, a unique, patented spray with hemoglobin, which transports oxygen from the air to the wound tissue, thus mitigating the oxygen deficiency. This unique medicinal product is manufactured by our partner company, SastoMed GmbH , and is now being successfully marketed under the Granulox brand name.

Witten, Germany, August 13, 2012 SastoMed GmbH, global licensee of the Sangui patented wound spray, has submitted the announced report covering the first 100 days of Granulox product sales. The report is available on www.sastomed.de . Its results meet and in some parts considerably exceed the expectations which were directed at the joint venture company by SanguiBioTech GmbH as the licenser. SastoMed assumes that the initial investments will have amortized by 2014.

Products & services

Similar companies nearby